NanoViricides is trading 9.17% up now at $1.30 after announcing first-patient dosing for its Phase II NV-387 oral-gummy Ebola trial is expected next week in the Democratic Republic of Congo, barring outbreak-related impediments. - The trial will evaluate NV-387 in Ebola patients at a treatment center in Ituri province. - Broader biotechnology strength and improving risk sentiment are providing additional support.